Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BIVINASDAQ:MRKRNASDAQ:RZLTNASDAQ:VERU Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$0.45$0.50$0.43▼$6.49$27.55M0.811.76 million shs787,191 shsMRKRMarker Therapeutics$3.93-5.1%$4.33$1.21▼$9.68$35.06M1.5418,289 shs12,990 shsRZLTRezolute$3.69+3.7%$2.72$0.72▼$3.72$148.08M1.29436,874 shs751,112 shsVERUVeru$1.11-9.8%$1.18$0.36▼$1.92$162.49M-0.472.32 million shs4.12 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie0.00%-3.59%-6.31%-64.24%-92.76%MRKRMarker Therapeutics0.00%-1.43%-3.50%+11.89%+223.44%RZLTRezolute0.00%+26.69%+33.83%+110.65%+69.52%VERUVeru0.00%-13.38%-3.15%+90.34%+18.27%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie1.794 of 5 stars3.35.00.00.02.80.00.0MRKRMarker Therapeutics4.0082 of 5 stars3.55.00.03.92.60.80.0RZLTRezolute3.3882 of 5 stars3.54.00.00.03.05.00.0VERUVeru1.4766 of 5 stars3.41.00.00.02.03.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie2.50Moderate Buy$8.001,671.87% UpsideMRKRMarker Therapeutics3.00Buy$11.00179.90% UpsideRZLTRezolute3.00Buy$8.80138.48% UpsideVERUVeru2.80Moderate Buy$4.00260.36% UpsideCurrent Analyst RatingsLatest VERU, RZLT, MRKR, and BIVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.005/16/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.005/14/2024VERUVeruB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.005/13/2024VERUVeruHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.005/6/2024VERUVeruHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $3.004/30/2024MRKRMarker TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$11.004/18/2024RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.004/18/2024RZLTRezoluteJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/15/2024VERUVeruOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $5.004/9/2024RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/28/2024VERUVeruRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.00(Data available from 5/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$0.42 per shareN/AMRKRMarker Therapeutics$3.31M10.59N/AN/A$1.58 per share2.49RZLTRezoluteN/AN/AN/AN/A$3.15 per shareN/AVERUVeru$13.48M12.05N/AN/A$0.22 per share5.05Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$50.26M-$0.94N/A∞N/AN/A-294.42%-129.46%8/21/2024 (Estimated)MRKRMarker Therapeutics-$8.24MN/A0.00N/AN/A-142.62%-39.89%-25.45%8/12/2024 (Estimated)RZLTRezolute-$51.79M-$1.14N/AN/AN/AN/A-60.90%-54.58%9/12/2024 (Estimated)VERUVeru-$93.15M-$0.34N/AN/AN/A-265.27%-130.13%-67.82%8/8/2024 (Estimated)Latest VERU, RZLT, MRKR, and BIVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024Q2 2024VERUVeru-$0.05-$0.07-$0.02-$0.07$3.00 million$4.14 million4/1/2024Q1 2024VERUVeruN/A-$0.09-$0.09-$0.10N/A$2.14 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A2.452.45MRKRMarker TherapeuticsN/A6.126.12RZLTRezoluteN/A11.8211.82VERUVeruN/A4.724.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%MRKRMarker Therapeutics22.39%RZLTRezolute82.97%VERUVeru47.16%Insider OwnershipCompanyInsider OwnershipBIVIBioVie4.80%MRKRMarker Therapeutics17.35%RZLTRezolute20.80%VERUVeru14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie1861.02 million58.09 millionOptionableMRKRMarker Therapeutics88.92 million7.37 millionNot OptionableRZLTRezolute5740.13 million31.79 millionNot OptionableVERUVeru189146.38 million125.60 millionOptionableVERU, RZLT, MRKR, and BIVI HeadlinesRecent News About These CompaniesMay 28 at 12:15 PM | bovnews.comIt’s an all-out bull run for Veru Inc (VERU) StockMay 27 at 8:51 PM | pharmiweb.comFuture of Contraceptives: Market Valued at $26.3 Billion in 2020, Expected to Reach $50.6 Billion by 2030May 27 at 5:55 PM | marketbeat.comAIGH Capital Management LLC Purchases New Stake in Veru Inc. (NASDAQ:VERU)May 26 at 6:54 AM | americanbankingnews.comMitchell Shuster Steiner Sells 63,379 Shares of Veru Inc. (NASDAQ:VERU) StockMay 25 at 4:34 PM | insidertrades.comInsider Selling: Veru Inc. (NASDAQ:VERU) CEO Sells 63,379 Shares of StockMay 25 at 9:48 AM | bovnews.comWhere are Investors’ Sentiments? Veru Inc (VERU) StockMay 24, 2024 | marketbeat.comVeru Inc. (NASDAQ:VERU) CEO Sells $77,956.17 in StockMay 22, 2024 | finance.yahoo.comIndividual investors account for 48% of Veru Inc.'s (NASDAQ:VERU) ownership, while institutions account for 25%May 22, 2024 | globenewswire.comVeru to Present at the Jefferies Global Healthcare ConferenceMay 20, 2024 | marketbeat.comWorth Venture Partners LLC Invests $616,000 in Veru Inc. (NASDAQ:VERU)May 20, 2024 | lutontoday.co.ukA&E Navigators at Luton and Bedford hospitals help young people facing violenceMay 20, 2024 | americanbankingnews.comVeru Inc. (NASDAQ:VERU) CEO Mitchell Shuster Steiner Sells 28,066 SharesMay 19, 2024 | americanbankingnews.comMitchell Shuster Steiner Sells 84,021 Shares of Veru Inc. (NASDAQ:VERU) StockMay 18, 2024 | insidertrades.comMitchell Shuster Steiner Sells 28,066 Shares of Veru Inc. (NASDAQ:VERU) StockMay 17, 2024 | investing.comVeru Inc. CEO sells over $246k in company stockMay 17, 2024 | investing.comVeru Inc. executive buys $9,999 in company stockMay 16, 2024 | marketbeat.comEquities Analysts Issue Forecasts for Veru Inc.'s Q3 2024 Earnings (NASDAQ:VERU)May 15, 2024 | globenewswire.comVeru Announces Steven B. Heymsfield M.D.May 14, 2024 | globenewswire.comVeru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology WeekMay 14, 2024 | marketbeat.comB. Riley Initiates Coverage on Veru (NASDAQ:VERU)May 14, 2024 | markets.businessinsider.comBuy Rating for Veru Inc. on Promising Enobosarm Trials and Strategic Market PositioningNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBioVieNASDAQ:BIVIBioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Marker TherapeuticsNASDAQ:MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.RezoluteNASDAQ:RZLTRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.VeruNASDAQ:VERUVeru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.